How should akathisia be managed in a patient?

Management of Akathisia

For patients with akathisia associated with antipsychotic therapy, lower the antipsychotic dose, switch to another antipsychotic, add a benzodiazepine, or add a beta-adrenergic blocking agent 1.

Stepwise Management Algorithm

First-Line Interventions

Dose reduction or antipsychotic switching should be attempted first if clinically feasible. The 2020 APA guidelines provide this as a 2C recommendation (suggestion with low-quality evidence), but this represents the most conservative approach that addresses the root cause 1. When switching antipsychotics, consider agents with lower akathisia liability—avoid high-potency typical antipsychotics and D2 partial agonists like aripiprazole, which commonly cause akathisia despite causing few other extrapyramidal symptoms 2.

Pharmacological Treatment Options

When dose reduction or switching is not feasible, add adjunctive medication based on the following hierarchy:

Most Effective Options (Based on 2024 Network Meta-Analysis):

1. Mirtazapine 7.5-15 mg daily (SMD -1.20; strongest effect size) 3, 4

   • Acts via 5-HT2a receptor antagonism
   • Well-tolerated with sedation as primary side effect
   • Evidence supports low doses specifically

2. Vitamin B6 600-1200 mg daily for ≥5 days (SMD -0.92) 3

   • Best efficacy-to-tolerance profile
   • Minimal side effects
   • Underutilized but evidence-supported

3. Propranolol 20-80 mg daily (SMD -0.78) 3, 5

   • Traditionally considered first-line
   • Contraindications: asthma, bradycardia, orthostatic hypotension
   • Requires careful titration
   • Evidence is actually modest despite widespread use

4. Benzodiazepines (lorazepam, clonazepam) 1, 5

   • Provide symptomatic relief
   • Risk of dependence with prolonged use
   • Useful for acute distress

Alternative Options:

• Biperiden 6 mg daily (anticholinergic; SMD -1.01) 3
• Trazodone 50 mg daily (5-HT2a antagonist; SMD -0.84) 3
• Mianserin 15 mg daily (5-HT2a antagonist; SMD -0.81) 3

Note: Anticholinergics are NOT consistently helpful for akathisia, unlike their effectiveness for acute dystonia and parkinsonism 6. The exception is biperiden, which showed efficacy in recent meta-analysis 3.

Critical Clinical Pitfalls

Recognition Challenges

Akathisia is frequently misdiagnosed as psychotic agitation, anxiety, or worsening psychosis 6, 2. This leads to inappropriate antipsychotic dose increases, worsening the condition. Patients describe feeling "locked in," needing to constantly move, or being in a "glass coffin" 7. The subjective distress is severe and associated with increased suicide risk and medication non-adherence 3.

Maintain high suspicion in:

• Patients with motor disabilities (symptoms may be masked)
• Those with drug-induced parkinsonism (overlapping symptoms)
• Patients under mechanical restraint (cannot express restlessness through movement) 2

Timing Considerations

• Mean onset: 18-21 days after starting causative medication 7
• Can occur with any antipsychotic, including those with low extrapyramidal side effect profiles (clozapine, quetiapine, aripiprazole, cariprazine) 2
• Drug-drug interactions can precipitate akathisia in previously stable patients—particularly fluoroquinolones (ciprofloxacin) combined with antipsychotics 8

Treatment Duration

Chronic and tardive akathisia may persist after drug withdrawal and prove resistant to pharmacological treatment 2. In resistant cases documented in palliative care, symptoms persisted for 4 weeks despite multiple interventions 7. Rotation between different pharmacological strategies may be optimal in resistant cases 2.

Practical Implementation

1. Systematically assess with validated scales (Barnes Akathisia Rating Scale) before starting antipsychotics and during titration 5

2. If akathisia develops:

   • First: Reduce antipsychotic dose or switch to lower-liability agent
   • Second: Add mirtazapine 7.5-15 mg OR vitamin B6 600-1200 mg
   • Third: If contraindications to above, use propranolol 20-80 mg
   • Fourth: Add benzodiazepine for acute distress

3. Avoid: Increasing antipsychotic dose, adding anticholinergics as first-line (except biperiden), prolonged benzodiazepine monotherapy

4. Monitor: Response within 5-14 days; if no improvement, rotate to alternative agent rather than continuing ineffective treatment

Quality of life impact is paramount—akathisia causes significant distress and unnecessary suffering when unrecognized or inadequately treated 7, 2.